Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...

EHA June 2026 guidelines endorse time-limited first-line CLL therapy based on TP53 and IGHV, informed by CLL17 showing fixed-duration targeted therapy noninferior to continuous ibrutinib. MRD-guided ...

In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted ...

Venetoclax plus acalabrutinib becomes the first fully oral, fixed-duration option for treatment-naïve CLL, adding a differentiated targeted approach to frontline regimen selection. A defined treatment ...

Error-corrected sequencing of non–B-cell fractions in CLL12/CLL14 detected CH in ~58% of CLL, with 35% meeting CHIP criteria. Cytotoxic regimens, especially chlorambucil-based therapy, were linked to ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) ...

Until recently, a chronic lymphocytic leukemia (CLL) diagnosis came with limited options and a lot of uncertainty. Today, long-term results show how much treatment has changed — and what patients and ...

Chronic lymphocytic leukaemia, which is the most reported type of leukaemia in adults. In the past ten years. There have been advances in medical research that have informed changes in how healthcare ...

Protein arginine methyltransferase 1 (PRMT1) serves as a crucial regulator of post-translational modifications of proteins. While PRMT1 has been implicated in the progression of various cancers, its ...